Metabolic Side-effects for Second-generation Antipsychotics

The University of Hong Kong (HKU)

Status: Completed

Conditions: Mental Disorders

Study type: Observational

Funder types: Other

Identifiers

NCT01280396

HKCTR-1205

Details and patient eligibility

About

Second-generation antipsychotics (SGAs), including clozapine, are commonly used nowadays as treatment for psychosis. There are increasing concerns about their related metabolic side-effects over weight gain, risks to cause glucose intolerance and hyperlipidemia, and a specific condition known as metabolic syndrome. All these side-effects might be associated with the increased risk of cardiovascular diseases and diabetes mellitus.

This study is to analyze the simple physical measurements (weight and height) and venous blood tests (for fasting blood glucose and lipid) results collected routinely since 2008 (recommended by the local hospital authority as a territory-wide "SGAs Monitoring Program") from those outpatients receiving SGAs (amisulpride, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone and ziprasidone) and/or clozapine, at a local psychiatric outpatient clinic in Hong Kong. The investigators hypothesized that there should be differential risks on metabolic side-effects amongst these SGAs.

Enrollment: 241 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• was ≥18 years of age
• out-patients
• had received any one of these antipsychotics: aripiprazole, amisulpride, clozapine, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone
• consented to provide physical measurements and venous blood samples

Exclusion criteria

• not consented to provide venous blood samples and/or physical measurement

Trial design

241 participants in 1 patient group

SGAs

Description:

patients receiving SGAs